After a couple of disappointing trials for Pfizer's
Earlier this year, an independent data monitoring board ended a trial testing Sutent against pancreatic islet cell tumors, a type of pancreatic cancer, because the drug was working better than placebo. When a drug is clearly working, trials are ended so that patients who are taking the placebo can be switched over to the effective drug, but the actual results are often saved for a scientific meeting.
Today investors got to see how effective Sutent really is against pancreatic islet cell tumors. The median time for progression of disease was more than double for patients taking Sutent compared to those taking placebo. That's pretty darn impressive.
The nice thing about expanding labels for drugs -- Sutent is already approved to treat two other kinds of cancer -- is that companies don't have to wait for approval to see an uptick in sales. Given the few treatment options for pancreatic islet cell tumors, doctors are likely to prescribe it off label before the drug is approved for that use. In fact, the company's presentation of the data at the World Congress on Gastrointestinal Cancer acts as a perfectly legal way to promote the use of the drug.
Sutent could use a little push to get sales growth back in gear; after growing sales 166% from 2006 to 2007 and 46% the following year, sales were up just 7% year over year in the first quarter of this year. Tough competition from Onyx Pharmaceuticals'
Pfizer might not find too many additional sales expanding into pancreatic islet cell tumors, though. The type of pancreatic cancer is fairly rare -- there might be just 600 to 1,200 patients diagnosed with it each year in the U.S. -- but there has been at least one famous sufferer: Steve Jobs of Apple
Investors in Pfizer are going to need to remain patient. It's going to take time to work through the merger with Wyeth and it'll take a while before Sutent becomes the multibillion blockbuster it's capable of becoming.
More from The Motley Fool
Whom Will Pfizer Buy in 2018?
Keep your eyes on these three drugmakers.
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.